Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves New Dosing Regimen for Pembrolizumab

Accelerated approval is based on data from the Cohort B of Study KEYNOTE-555
30 Apr 2020
Cancer Immunology and Immunotherapy

On 28 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA, Merck) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen.

The approval was based on pharmacokinetic modelling and exposure-response analyses that compared the predicted exposure of pembrolizumab 400 mg every six weeks to observed exposures of pembrolizumab in patients who received pembrolizumab at 2 mg/kg every three weeks, 200 mg every three weeks, and 10 mg/kg administered every two weeks.

The pharmacokinetic modelling was supported by additional exposure-response analyses across the pembrolizumab development programme and an interim analysis of pharmacokinetics and overall response rate (ORR) in a cohort of patients (Cohort B) enrolled in Study KEYNOTE-555 (NCT03665597).

Cohort B of Study KEYNOTE-555 was an international, single-arm, multicentre study that enrolled 101 patients with advanced or metastatic melanoma who had not received prior PD-1, PD-L1, or CTLA-4 inhibitors (other than CTLA-4 inhibitors in the adjuvant setting).

The ORR was 39% (95% confidence interval 24, 55) in the first 44 patients enrolled in KEYNOTE-555.

The study findings were presented at AACR Virtual Annual Meeting I.

For additional safety and efficacy information, and recommended dosing regimens, view the full prescribing information for KEYTRUDA here.

This new dosing regimen is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

This application was approved more than five months prior to the FDA goal date.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Centre of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings